Summit Therapeutics (SMMT) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to -$238.9 million.
- Summit Therapeutics' Enterprise Value fell 15385.77% to -$238.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$238.9 million, marking a year-over-year decrease of 15385.77%. This contributed to the annual value of -$412.3 million for FY2024, which is 12140.49% down from last year.
- According to the latest figures from Q3 2025, Summit Therapeutics' Enterprise Value is -$238.9 million, which was down 15385.77% from -$298.2 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Enterprise Value ranged from a high of -$28.8 million in Q2 2024 and a low of -$648.6 million during Q4 2022
- Its 5-year average for Enterprise Value is -$211.6 million, with a median of -$192.6 million in 2023.
- Per our database at Business Quant, Summit Therapeutics' Enterprise Value skyrocketed by 8662.69% in 2024 and then crashed by 93704.18% in 2025.
- Quarter analysis of 5 years shows Summit Therapeutics' Enterprise Value stood at -$71.8 million in 2021, then tumbled by 803.47% to -$648.6 million in 2022, then skyrocketed by 71.29% to -$186.2 million in 2023, then tumbled by 121.4% to -$412.3 million in 2024, then surged by 42.07% to -$238.9 million in 2025.
- Its last three reported values are -$238.9 million in Q3 2025, -$298.2 million for Q2 2025, and -$361.3 million during Q1 2025.